Simultaneous Targeting of 5-Lox-Cox and EGFR Blocks Progression of Pancreatic Ductal Adenocarcinoma

Oncotarget - United States
doi 10.18632/oncotarget.5396
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

EGFR, but Not COX‑2, Protein in Resected Pancreatic Ductal Adenocarcinoma Is Associated With Poor Survival

Oncology Letters
Cancer ResearchOncology
2019English

Fibroblast Activation Protein Augments Progression and Metastasis of Pancreatic Ductal Adenocarcinoma

JCI insight
Medicine
2017English

Increased CDC20 Expression Is Associated With Pancreatic Ductal Adenocarcinoma Differentiation and Progression

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2012English

Molecular Targeting of Cell-Permeable Peptide Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation

Oncotarget
Oncology
2017English

Upregulation of miR-194 Contributes to Tumor Growth and Progression in Pancreatic Ductal Adenocarcinoma

Oncology Reports
MedicineCancer ResearchOncology
2013English

UBL4A Inhibits Autophagy-Mediated Proliferation and Metastasis of Pancreatic Ductal Adenocarcinoma via Targeting LAMP1

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Features of Immunophenotype of Pancreatic Ductal Adenocarcinoma

Zaporozhye Medical Journal
2014English

A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma

Nucleic Acid Therapeutics
BiochemistryMolecular MedicineDrug DiscoveryGeneticsMolecular Biology
2017English

Progression of Pancreatic Adenocarcinoma Is Significantly Impeded With a Combination of Vaccine and COX-2 Inhibition

Journal of Immunology
AllergyImmunology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy